Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368671 | 0.84 | MEN1 (0.41) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL29500393 | 0.82 | MEN1 (0.56) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL65955 | 0.82 | MEN1 (0.56) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL17850502 | 0.81 | TRPV4 (0.44) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL6240708 | 0.81 | CCR4 (0.44) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL29434897 | 0.81 | CCR4 (0.44) | TRPV4MEN1KMT2ASLC22A12RXFP1 | |
| SCHEMBL6254835 | 0.81 | HSD11B1 (0.40) | TRPV4MEN1KMT2ASLC22A12HSD11B1 | |
| SCHEMBL2512044 | 0.81 | CA2 (0.46) | MEN1KMT2ASLC22A12CYP2C9 | |
| SCHEMBL30681743 | 0.81 | SLC22A12 (0.39) | TRPV4MEN1KMT2ASLC22A12HSD11B1 | |
| SCHEMBL3062954 | 0.81 | MEN1 (0.43) | MEN1KMT2ASLC22A12HSD11B1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250174718-A1 | GEL ELECTROLYTE COMPOSITION AND SECONDARY BATTERY INCLUDING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-29 | — | — | US | disclosed |
| CN-118786552-A | Gel electrolyte composition and secondary battery comprising same | 韩国化学研究院 | 2024-10-15 | — | — | CN | disclosed |
| WO-2023128366-A1 | GEL ELECTROLYTE COMPOSITION AND SECONDARY BATTERY COMPRISING SAME | 한국화학연구원 | 2023-07-06 | — | — | WO | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1763361-A2 | STEROID SPARING AGENTS AND THEIR USE | Elan Pharmaceuticals, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1185261-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1185261-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076495-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0799198-B1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0799198-A4 | — | — | 1997-10-15 | — | — | EP | disclosed |
| EP-0799198-A1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5545669-A | Anti-inflammatory compounds | SMITHKLINE BEECHAM CORPORATION | 1996-08-13 | — | — | US | disclosed |
| WO-1995033461-A1 | ANTI-INFLAMMATORY COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | TRPV4 2291/4885MEN1 4369/4885KMT2A 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.